๐
๐ Business
AstraZeneca shares drop over 10% after rare heart drug trial fails
AstraZeneca's shares fell more than 10% after a clinical trial of a new heart drug failed to show benefits for patients with a rare disease. The setback represents one of the company's steepest single-day declines in recent memory. The failure has shaken investor confidence in the pharmaceutical giant's pipeline.
Comments
No comments yet
Comments
No comments yet โ be the first to weigh in ๐
No comments yet. Be the first!